CBD-OS for developmental epileptic encephalopathy (DEE)
Part of Brain & nervous system clinical trials.
This trial tests an investigational medicine called CBD-OS for people with a type of severe epilepsy called developmental and epileptic encephalopathy (DEE). The study aims to see if this treatment is safe and helps control seizures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 1 year old.
- Have a diagnosis of DEE as defined by the study doctors.
- Be on at least one stable anti-seizure medicine or another epilepsy treatment (like a ketogenic diet or nerve stimulation) that has not changed for at least 28 days.
- Have had imaging or genetic testing to find the cause of your DEE, or be willing to do so.
- Have not taken Epidiolex before or be willing to stop it at least 28 days before the study starts.
- Not be taking the medicine felbamate for less than 1 year.
- Not have other serious brain conditions that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called LP352 for children and adults with certain types of epilepsy (Dravet syndrome, Lennox-Gastaut syndrome, or other developmental and epileptic encephalopathies). It's for people who already completed a previous study of LP352 and may benefit from continued treatment.
This trial tests a new cannabidiol (CBD) liquid medicine for people with focal epilepsy (seizures that start in one part of the brain). It looks at whether the medication can help reduce seizures when added to your current seizure medications.
This trial tests a new drug called BMB-101 for people with absence epilepsy (including Jeavons syndrome) or developmental epileptic encephalopathies (DEE) like Dravet or Lennox-Gastaut. It aims to see if the drug can reduce seizure frequency and is safe.
This trial provides access to cannabidiol (CBD), a marijuana-derived compound, for children with severe epilepsy that hasn't improved with standard medications. The goal is to see if CBD can help reduce seizures in this difficult-to-treat group.
This study tests whether a cannabis-based medicine can reduce seizures in people with epilepsy that hasn't improved with other treatments. It may offer a new option for those who continue to have seizures.
This trial tests if adding cannabidiol (CBD) to your child's current seizure medicines can reduce seizures. It uses a personalized approach to see if CBD works for each child.
Hear when a new Developmental and Epileptic Encephalopathy (DEE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.